EXACT SCIENCES CORP (EXAS)
US30063P1057 - Common Stock
First Week of July 2024 Options Trading For EXACT Sciences (EXAS)
3 Stocks at the Forefront of Personalized Medicine Trend
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates...
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence Score® results to refine distant recurrence risk estimates...
A Bull Market Is Coming: 1 Incredible Growth Stock to Buy Hand Over Fist Before It Soars 729%, According to Cathie Wood's Ark Invest
If the fund manager's calculations prove to be correct, Tesla shareholders could enjoy sevenfold returns over the coming four years. Is she right?
The 3 Best Digital Health Stocks for Personalized Medicine
Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.
Cantor Fitzgerald cuts Mainz to neutral, cites liquidity concerns (NASDAQ:MYNZ)
Cantor Fitzgerald lowered its rating on Mainz Biomed (MYNZ) to neutral, citing concerns that the company will need an additional $25M in capital in next year. Read more here.
3 Biotech Stocks With Big-Time Breakthrough Potential
The biotech industry is filled with opportunity with these sure winners, pick up high-potential stocks like these and ride the wave.
2 Revolutionary Stocks That Could Turn $1,000 Into $2,000 by 2030
Don't miss out on these potentially market-beating stocks.
Exact Sciences sues Geneoscopy for alleged patent infringement (EXAS)
Exact Sciences (EXAS) has filed a lawsuit alleging that Geneocopy's ColoSense infringes upon a key patent for its colorectal cancer test Cologuard. Read more here.
Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit...
3 Stocks to Love Despite All of the Wall Street Hate
We're in the early stages of a bull market, so the Street hates most smaller companies, but these contrarian stock picks are set to soar.
Interesting EXAS Put And Call Options For April 2024
7 Biotech Stocks to Buy for Big-Time Gains
Biotech stocks can be big winners because they're at the forefront of scientific innovation and push the boundaries of medical research.
Exact Sciences (EXAS) Q3 2023 Earnings Call Transcript
EXAS earnings call for the period ending September 30, 2023.
Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth
The company makes a diagnostic tool to detect colon cancer.
Exact Sciences Announces Third-Quarter 2023 Results
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated...
Exact Sciences to participate in November investor conferences
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will...
Interesting EXAS Put And Call Options For January 2026
RSI Alert: EXACT Sciences (EXAS) Now Oversold
3 Comeback Stocks to Buy Before They Soar Again in 2024
High Treasury yields were triggered by economic growth, not inflation. As a result, there are likely to be many comeback stocks.
3 Comeback Stocks to Buy Before They Soar Again in 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many investors are probably upset that the yields of the 10-year treasury bonds...
Cathie Wood's Biggest Holdings Are Tumbling, Including Tesla
Even Ark Invest's big 2023 winners are well off highs.
Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the...
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data...
7 Winning Stocks That Will Make You an Investing Champion
Inflation is under control and economic growth is strong. Here are seven winning stocks to buy to exploit the positive trends.
Cathie Wood’s 3 Favorite AI Stocks: October 2023
Despite the surprising sale of her Nvidia stock, investors can still look to Cathie Wood for guidance on future purchases of AI stocks.
7 Affordable Stocks to Invest in as America’s Population Ages
Stocks for an aging population include some surprisingly youthful products and firms not commonly associated with seniors.
Exact Sciences stock upgraded at Piper Sandler (NASDAQ:EXAS)
Exact Sciences (EXAS) has been upgraded by Piper Sandler, citing an attractive buying opportunity and a high growth potential in cancer screening. Read more here.
Exact Sciences schedules third quarter 2023 earnings call
/PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to...